World's Best Scientists 2026 revealed!
Award Badge
Microbiology
South Africa
2026

D-Index & Metrics

Microbiology

D-Index
70
Citations
24465
World Ranking
1897
National Ranking
9

Medicine

D-Index
72
Citations
25564
World Ranking
19774
National Ranking
46

Research.com Recognitions

  • 2026 - Research.com Microbiology in South Africa Leader Award

Overview

Ian Sanne is affiliated with the University of the Witwatersrand in South Africa. Their research primarily focuses on the field of Medicine, with particular expertise in Infectious Diseases, Epidemiology, Virology, Health, and Emergency Medicine.

They have contributed extensively to topics such as HIV/AIDS Research and Interventions, SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, COVID-19 Clinical Research Studies, HIV/AIDS drug development and treatment, Vaccine Coverage and Hesitancy, and HIV, Drug Use, Sexual Risk.

Frequent coauthors in Ian Sanne's work include Charles Chasela, Linda-Gail Bekker, Glenda Gray, Nigel Garrett, and Ameena Goga.

Prominent venues where Ian Sanne's research has been published include UNC Libraries, bioRxiv (Cold Spring Harbor Laboratory), South African Medical Journal, Clinical Infectious Diseases, and PLoS ONE.

Significant recent papers authored or coauthored by Ian Sanne are:

  • High Asymptomatic Carriage With the Omicron Variant in South Africa, 2022, Clinical Infectious Diseases
  • Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial, 2021, The Lancet Global Health
  • Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial, 2020, JAIDS Journal of Acquired Immune Deficiency Syndromes
  • Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study, 2021, New England Journal of Medicine
  • Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts, 2022, Scientific Reports

Best Publications

  • Prevention of HIV-1 Infection with Early Antiretroviral Therapy

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

    Diane V. Havlir;Michelle A. Kendall;Prudence Ive;Johnstone Kumwenda

  • Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

    Andrew R. Zolopa;Janet Andersen;Lauren Komarow;Ian Sanne

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

    Susan E. Dorman;Payam Nahid;Ekaterina V. Kurbatova;Patrick P.J. Phillips

  • High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

    Martin J Boeree;Norbert Heinrich;Rob Aarnoutse;Andreas H Diacon

  • Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial

    Sydney Rosen;Sydney Rosen;Mhairi Maskew;Matthew P. Fox;Matthew P. Fox;Cynthia Nyoni

  • Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

    Ian Sanne;Herve Mommeja-Marin;John Hinkle;John A. Bartlett

  • Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

    Ian Sanne;Catherine Orrell;Matthew P Fox;Francesca Conradie

  • Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?

    Annelies Van Rie;Liesl Page-Shipp;Lesley Scott;Ian Sanne

  • Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

    Ian Sanne;Peter Piliero;Kathleen Squires;Alexandra Thiry

  • Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

    Josephine M Bryant;Simon R Harris;Julian Parkhill;Rodney Dawson

  • Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.

    Diane V. Havlir;Haileyesus Getahun;Ian Sanne;Paul Nunn

  • Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study

    Lesley E. Scott;Kerrigan McCarthy;Natasha Gous;Matilda Nduna

  • A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS

    Jose A. Vazquez;Daniel J. Skiest;Leopoldo Nieto;Rebeca Northland

  • Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

    Robert Leo Murphy;Ian Sanne;Pedro Cahn;Praphan Phanuphak

  • SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients

    Mohau S Makatsa;Marius B Tincho;Jerome M Wendoh;Sherazaan D Ismail

  • The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa

    Gesine Meyer-Rath;Gesine Meyer-Rath;Kathryn Schnippel;Lawrence Long;William MacLeod;William MacLeod

  • Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

    Philip M. Grant;Lauren Komarow;Janet Andersen;Irini Sereti

  • Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.

    David W. Haas;John A. Bartlett;Janet W. Andersen;Ian Sanne

Frequent Co-Authors

Wendy S. Stevens
Wendy S. Stevens National Health Laboratory Service
Luis J. Montaner
Luis J. Montaner The Wistar Institute
Beatriz Grinsztejn
Beatriz Grinsztejn Oswaldo Cruz Foundation
Michael M. Lederman
Michael M. Lederman Case Western Reserve University
Robin Wood
Robin Wood University of Cape Town
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Diane V. Havlir
Diane V. Havlir University of California, San Francisco
Gavin J. Churchyard
Gavin J. Churchyard Aurum Institute
Audrey Pettifor
Audrey Pettifor University of North Carolina at Chapel Hill
Kenneth H. Mayer
Kenneth H. Mayer Harvard Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to Microbiology can broaden your career options and offer flexible learning opportunities. For those interested in the health sciences, consider medical degrees online that pay well, which can lead to rewarding positions in healthcare and research.

Public health is another complementary field. Many students find online mph programs easy to get into, allowing for a smoother transition into careers focusing on community health, epidemiology, or healthcare administration.

With a strong foundation in biology and psychology, becoming a child life specialist is also a viable pathway. Understanding child life specialist salary with bachelor degree information can help set realistic expectations while planning your career trajectory.

Additionally, some online colleges that accept felons offer inclusive opportunities for those with records seeking a fresh start in education. These programs emphasize accessibility and can support diverse student backgrounds as they work toward degrees in fields related to microbiology and health sciences.

Best Scientists Citing Ian Sanne

Trending Scientists

Recently Published Articles